Skip to Content

Living Cell Technologies Ltd ADR LVCLY

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Living Cell Technologies Ltd is an Australasian biotechnology company improving the wellbeing of people with serious diseases by discovering, developing, and commercializing regenerative treatments that restore function using naturally occurring cells. Its lead product, NTCELL, is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

Contact
C/O Mertons Corporate Services, 330 Collins Street, Level 7
Melbourne, VIC, 3000, Australia
T +61 386899997
Sector Healthcare
Industry Biotechnology
Most Recent Earnings
Fiscal Year End Jun 30, 2020
Stock Type
Employees 48